[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xuanwu Hospital, Beijing\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":622},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,172,0,25,[9,48,71,98,125,148,180,206,237,258,281,304,328,354,381,403,428,448,465,495,514,532,548,575,601],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100636513",false,"NCT07566663","Preventive Analgesia With Anrikefon in Laparoscopic Cholecystectomy","Effect of Preventive Analgesia With Anrikefon on Postoperative Acute Pain and Rehabilitation Process in Adult Patients Undergoing Laparoscopic Cholecystectomy","ANIPAP","Inclusion Criteria:\n\n1. ASA physical status classification I-III;\n2. Age 18-65 years;\n3. Scheduled for elective laparoscopic cholecystectomy;\n4. Voluntary signed informed consent;\n5. BMI between 18-28 kg\u002Fm²;\n6. No history of general anesthesia surgery within the past 3 months.\n\nExclusion Criteria:\n\n1. Severe cardiovascular disease, respiratory disease, or psychiatric disorders;\n2. Severe renal insufficiency;\n3. Recent use of diuretics or compound medications containing diuretics;\n4. Continuous use of opioid analgesics for more than 10 days within the past 3 months;\n5. Use of medications with unknown half-life affecting analgesic efficacy within 14 days prior to randomization;\n6. Pregnant women, lactating women, or those planning pregnancy in the near future;\n7. History of hypersensitivity to study medications.","ALL","18 Years","65 Years",{"count":21,"type":22},274,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study will determine the optimal timing for Anrikefon administration. It will also assess the quality of patient recovery. Laparoscopic cholecystectomy (LC) is a routine surgical procedure. However, the incidence of acute visceral and incision pain is high, reaching 50% to 70%. This pain significantly impairs patient recovery.\n\nAnrikefon is novel peripherally restricted κ-opioid receptor agonist. It has very low brain penetration. This property reduces central nervous system side effects and respiratory depression. Preventive analgesia blocks the transmission of nociceptive stimuli to the central nervous system. It reduces postoperative pain sensitization and intensity. Currently, research on Anrikefon for preventive analgesia in LC patients is limited. It impacts on the recovery process is not yet fully understood. This study will compare drug administration before anesthesia induction with intra-operative administration.\n\nParticipants will be assigned to one of two groups with equal probability using computer-generated random numbers. Patients in the Preventive Analgesia group will receive Anrikefon injection 15 minutes before anesthesia induction. Bridging Analgesia group is the control group. Patients in this group will receive Anrikefon immediately after the gallbladder is detached from the liver. Both groups will receive the identical drug dosage of 1 μg\u002Fkg.\n\nBoth treatment groups will receive identical care beyond the time of Anrikefon administration. All patients will undergo standardized anesthesia management. Parecoxib sodium 40 mg will be injected for rescue analgesia if NRS score \\> 4. We will analyze the primary, secondary, and exploratory outcome measures after surgery, aiming to explore the optimal timing of Anrikefon and its impact on the patient's recovery process.",[28],"Postoperative Pain",[30,31,32,33,34],"Preventive Analgesia","Laparoscopic Cholecystectomy","Postoperative Acute Pain","Visceral Pain","Anrikefon","RECRUITING","2026-06-29",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":39},"2026-06-02",{"date":43,"type":22},"2028-06-30",{"name":45,"class":46},"Xuanwu Hospital, Beijing","OTHER",1,{"id":49,"slug":4,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":47},"100508545","NCT05901818","Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease","Safety and Efficacy of Autologous Induced Neural Stem Cell-derived Dopaminergic Precursor Cells in the Treatment of Parkinson's Disease","Inclusion Criteria:\n\nAges between 30 and 85 years, males or females; Diagnosed to be Parkinson's disease patients according to MDS Parkinson's disease diagnostic criteria; Disease history over 3 years; Hoehn and Yahr Stage less than or equal to 4 during the medication \"on\" time; Responsive to levodopa treatment (Maximum rate of improvement in MDS-UPDRS, part 3, is over 30%).\n\nExclusion Criteria:\n\nAtypical Parkinsonian syndrome or secondary Parkinsonian syndrome; Accompanied with other central nervous system diseases; With other severe systemic diseases or dysfunction; With severe psychiatric disorders; Subjects are using hormone or cytotoxic drugs and cannot stop taking the drug during the trial; With cognitive disorders (MMSE\\\u003C24); With severe dyskinesia (MDS-UPDRS part 4, score in 4.1\u002F4.2 ≥ 2); Subjects have undergone previous brain surgery; Subjects are long-term user of anticoagulant; Subjects have intracranial lesions which may affect the surgery or follow-up studies as assessed by imaging; Subjects are unable to undergo MRI or AV133 PET examination; Pregnancy or in preparation for pregnancy; Not suitable to participate in this clinical trial as assessed by the study investigators\u002Fphysicians.","30 Years","85 Years",{"count":57,"type":22},6,[59],"PHASE1","This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.",[62],"Parkinson's Disease",[64],"Autologous; iNSC; DA precursor cells; Parkinson's Disease; Cell therapy; Stereotaxic injection",{"date":38,"type":39},{"date":67,"type":39},"2021-04-01",{"date":69,"type":22},"2028-12-31",{"name":45,"class":46},{"id":72,"slug":4,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":81,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":97,"locationsCount":4},"100644160","NCT07665255","CIRP and Cathepsin B in Neuroinflammation After Intracerebral Hemorrhage","A Prospective Observational Case-Control Study of Peripheral Blood CIRP, Cathepsin B, and Related Inflammatory Biomarkers in Patients With Intracerebral Hemorrhage","CIRP-ICH","Inclusion Criteria:\n\nIntracerebral hemorrhage group:\n\nAge 18 years or older Diagnosis of intracerebral hemorrhage confirmed by head CT or MRI Supratentorial hemorrhage No surgical treatment Hematoma volume less than 30 mL Admission within 24 hours after symptom onset The participant or the legally authorized representative\u002Fnext of kin is able to provide written informed consent\n\nHealthy control group:\n\nAge 18 years or older Recruited from the hospital health examination center No history of stroke, intracerebral hemorrhage, cerebral infarction, or other major neurological diseases No severe active infection, severe immune disease, hematologic disease, or end-stage severe heart, liver, or renal failure No acute infection, trauma, or other obvious stress state within the previous 2 weeks Able to provide written informed consent\n\nExclusion Criteria:\n\nIntracerebral hemorrhage group:\n\nTraumatic intracerebral hemorrhage Secondary intracerebral hemorrhage caused by brain tumor, cerebrovascular malformation, aneurysm, or hemorrhagic transformation of infarction Severe active infection, severe immune disease, or hematologic disease End-stage severe heart, liver, or renal failure Pregnant or lactating women Any other condition judged unsuitable by the investigator\n\nHealthy control group:\n\nHistory of stroke, intracranial hemorrhage, brain tumor, or other major neurological diseases Severe active infection, severe immune disease, or hematologic disease End-stage severe heart, liver, or renal failure Pregnant or lactating women Any other condition judged unsuitable by the investigator",true,{"count":80,"type":22},60,"1 Day","OBSERVATIONAL","This is a single-center, investigator-initiated, prospective observational case-control study. Patients with intracerebral hemorrhage and healthy controls will be enrolled at Xuanwu Hospital, Capital Medical University. Peripheral venous blood samples will be collected for measurement of CIRP, Cathepsin B, and related inflammatory biomarkers. Clinical and imaging data will also be collected in the intracerebral hemorrhage group. The study aims to compare biomarker levels between patients with intracerebral hemorrhage and healthy controls and to explore the potential role of these biomarkers in neuroinflammation after intracerebral hemorrhage. No investigational treatment will be administered.",[85,86],"Intracerebral Hemorrhage","Nontraumatic Intracerebral Hemorrhage",[88,89,90],"Neuroinflammation","cirp","Cathepsin B","NOT_YET_RECRUITING","2026-06-22",{"date":94,"type":39},"2026-06-24",{"date":38,"type":22},{"date":69,"type":22},{"name":45,"class":46},{"id":99,"slug":4,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":114,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100635432","NCT07552610","Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy for Acute Anterior Circulation Large-Vessel Occlusion","Efficacy and Safety of Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy in Acute Anterior Circulation Large-Vessel Occlusion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* 1.Symptoms and signs consistent with focal ischemia in the anterior circulation;\n* 2.Large vessel occlusion of the anterior circulation (internal carotid artery, M1\u002FM2 segment of the middle cerebral artery) confirmed by CTA\u002FMRA\u002FDSA;\n* 3.Undergoing mechanical thrombectomy;\n* 4.Age between 18-80 years, both male and female;\n* 5.Pre-stroke modified Rankin Scale (mRS) score ≤1;\n* 6.Time from symptom onset to thrombectomy ≤24 hours, including wake-up stroke or unwitnessed stroke; symptom onset is defined as the \"last known well\" (LKW);\n* 7.National Institutes of Health Stroke Scale (NIHSS) score ≥6 at admission;\n* 8.ASPECTS ≥3 for anterior circulation occlusion;\n* 9.Written informed consent provided by the patient or their legal representative.\n\nExclusion Criteria:\n\n* 1．Simultaneous acute occlusion of both the anterior and posterior circulation, or bilateral acute large-vessel occlusion in the anterior circulation;\n* 2．Failure to obtain a baseline NIHSS score before sedation or intubation by a neurologist or emergency physician;\n* 3．Seizure at stroke onset that precludes assessment of the baseline NIHSS score;\n* 4．Bilateral dilated pupils;\n* 5．Known allergy to sivelestat sodium or any of its excipients;\n* 6．Severe allergy or absolute contraindication to iodinated contrast agents;\n* 7．Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg that cannot be controlled with antihypertensive therapy;\n* 8．Blood glucose \\\u003C50 mg\u002FdL (2.8 mmol\u002FL) or \\>400 mg\u002FdL (22.2 mmol\u002FL);\n* 9．Platelet count \\\u003C50 \\* 10⁹\u002FL;\n* 10．Hereditary or acquired bleeding tendency, coagulation factor deficiency, current oral anticoagulant use with INR \\>1.7, or oral anticoagulant treatment within the previous 48 hours;\n* 11．Severe renal failure, defined as serum creatinine \\>3.0 mg\u002FdL (265.2 μmol\u002FL), glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin, or requirement for hemodialysis or peritoneal dialysis;\n* 12．Inability to complete the 90-day follow-up (e.g., no fixed residence or overseas patients);\n* 13．Suspected vasculitis or septic embolism;\n* 14．Suspected aortic dissection;\n* 15．Evidence of intracranial tumor (except small meningioma), acute intracranial hemorrhage, tumor, or arteriovenous malformation;\n* 16．Significant mass effect with midline shift;\n* 17．Evidence of internal carotid artery dissection causing flow limitation;\n* 18．Neurological disease or psychiatric disorder that may interfere with evaluation of the patient's condition;\n* 19．Pregnant or breastfeeding women;\n* 20．Confirmed rheumatic or autoimmune disease with long-term use of immunosuppressants or corticosteroids;\n* 21．Current treatment with chemotherapy or other immunomodulatory agents (e.g., recombinant human granulocyte colony-stimulating factor, Xuebijing, or ulinastatin);\n* 22．Participation in another clinical trial that may interfere with the results of this study;\n* 23．Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation or may pose a significant risk to the patient.","80 Years",{"count":106,"type":22},868,[25],"Stroke remains a major global health burden, with acute ischemic stroke (AIS) accounting for more than 65% of all cases. Endovascular thrombectomy (EVT) has been established as a standard treatment for large vessel occlusion (LVO) stroke; however, \"futile recanalization\" remains common, with many patients failing to achieve favorable functional outcomes despite successful vessel reperfusion. Increasing evidence indicates that neutrophils and neutrophil extracellular traps (NETs) play important roles in post-reperfusion inflammation, thrombosis, and microcirculatory dysfunction, which may contribute to thrombolysis resistance and poor prognosis. Neutrophil elastase (NE), a key component associated with NETs, may further aggravate vascular injury and thrombus formation.\n\nSivelestat Sodium is a selective NE inhibitor that has demonstrated anti-inflammatory and organ-protective effects in patients with acute respiratory distress syndrome and in experimental models of cerebral ischemia. It may help preserve blood-brain barrier integrity, reduce brain edema, and improve neurological outcomes. Based on these findings, this study is designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of sivelestat sodium as an adjunct to EVT in patients with acute anterior circulation large-vessel occlusive stroke within 24 hours of onset. The results of this study are expected to provide further clinical evidence for anti-inflammatory adjunctive treatment strategies aimed at reducing futile recanalization and improving functional outcomes in AIS.",[110,111,112,113],"Acute Ischemic Stroke","Large Vessel Occlusion","Thrombectomy","Neutrophil Extracellular Trap Formation",[115,116,117],"Endovascular Thrombectomy","Sivelestat Sodium","Neutrophil elastase",{"date":119,"type":39},"2026-06-25",{"date":92,"type":39},{"date":122,"type":22},"2029-05-31",{"name":45,"class":46},2,{"id":126,"slug":4,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":124},"100632850","NCT07519044","Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion","Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study-IAT-GIANT (Ganglioside GM1 to Improve Outcomes in Anterior CirculatioN Thrombectomy)","IAT-GIANT","Inclusion Criteria:\n\n* 1.Age ≥18 years and ≤80 years\n* 2.Symptoms and signs consistent with anterior circulation ischemia;\n* 3.Computed tomography angiography (CTA) \u002Fmagnetic resonance angiography (MRA) \u002Fdigital subtraction angiography (DSA) confirmed occlusion of intracranial segment of internal carotid artery (ICA) or M1\u002FM2 segments of the middle cerebral artery (MCA M1\u002FM2);\n* 4.Acute ischemic stroke (AIS) selected for emergency endovascular treatment;\n* 5.Premorbid mRS ≤1;\n* 6.Time from symptom onset to randomization was within 24 hours, including patients with wake-up stroke or unwitnessed stroke; The time of symptom onset was defined as the Last Known Well (LKW);\n* 7.National Institutes of Health Stroke Score (NIHSS) ≥6 at admission;\n* 8.ASPECTS ≥3;\n* 9.Informed consent obtained from the patient or his\u002Fher legal representative.\n\nExclusion Criteria:\n\n* 1.Simultaneous acute occlusion of large vessels in both the anterior and posterior circulation or bilateral cerebral hemispheres.\n* 2.Baseline NIHSS is not obtained by a neurologist or emergency physician prior to sedation or intubation;\n* 3.Seizures at stroke onset which would preclude obtaining a baseline NIHSS;\n* 4.Bilateral dilated pupils;\n* 5.Allergy to GM1 or excipients;\n* 6.Severe contrast allergy or absolute contraindication to iodinated contrast;\n* 7.Systolic pressure \\>185 mmHg or diastolic pressure \\>110 mmHg, and cannot be controlled by antihypertensive drugs;\n* 8.Blood glucose \\\u003C50 mg\u002Fdl (2.8 mmol\u002FL) or \\>400 mg\u002Fdl (22.2 mmol\u002FL);\n* 9.Platelet \\\u003C50\\*10\\^9\u002FL;\n* 10.Known genetic or acquired bleeding diathesis, deficiency of anticoagulant factors, or oral anticoagulant drugs and INR \\> 1.7, or treated with direct oral anticoagulant agents in the prior 48 hours;\n* 11.Known Severe renal Failure as defined by a serum creatinine \\> 3.0 mg\u002Fdl (or 265.2 μmol\u002Fl) or glomerular filtration rate (GFR) \\\u003C30, or patient requires hemodialysis or peritoneal dialysis;\n* 12.Patients that cannot complete 90-day follow-up (e.g. no fixed residence, overseas patients, etc.);\n* 13.Presumed vasculitis or septic embolization;\n* 14.Suspicion of aortic dissection;\n* 15.Evidence indicates intracranial tumors (excluding small meningiomas), acute intracranial hemorrhage, tumors, or arteriovenous malformations (AVMs).\n* 16\\. Significant mass effect causing midline shift.\n* 17\\. The patient has neurological disease or mental disorder before onset, which affects the assessment of the condition;\n* 18.Females who are pregnant or in lactation;\n* 19.Hereditary glycolipid metabolic disorders (ganglioside storage diseases, such as familial amaurotic idiocy, retinal degenerative diseases);\n* 20.Autoimmune diseases, spine injuries, demyelinating diseases (e.g., Guillain-Barre syndrome)\n* 21.Participating in other clinical trials that could confound the evaluation of the study;\n* 22.Other circumstances that the investigator considers inappropriate for participation or may pose a significant risk to patients.",{"count":106,"type":22},[134],"PHASE4","Stroke is a leading cause of global mortality and morbidity, with acute ischemic stroke (AIS) accounting for approximately 65.3% of cases and resulting in roughly 3.4 million new cases annually in China. While endovascular thrombectomy (EVT) is the recommended first-line therapy for large vessel occlusion (LVO), achieving 80-90% recanalization, fewer than 50% of patients reach functional independence (mRS 0-2) due to \"futile recanalization\" caused by mechanisms like no-reflow and reperfusion injury. Monosialotetrahexosylganglioside (GM1) is a unique glycosphingolipid that crosses the blood-brain barrier to provide neuroprotection by suppressing oxidative stress, excitotoxicity, and apoptosis while promoting neurogenesis. Although Phase III trials like the FOCUS study confirmed GM1's safety and efficacy in AIS populations, its benefit specifically for patients undergoing mechanical thrombectomy remains unkown. Therefore, the IAT-GIANT study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of adjunctive GM1 in improving 90-day functional outcomes for AIS-LVO patients treated with EVT.",[137,110],"Stroke",[139,140,141],"GM1","Mechanical Thrombectomy","Acute Anterior Circulation Large Vessel Occlusion",{"date":94,"type":39},{"date":144,"type":39},"2026-05-14",{"date":146,"type":22},"2028-08-31",{"name":45,"class":46},{"id":149,"slug":4,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":169,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":47},"100644087","NCT07665827","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage: A Multicenter, Prospective, Cluster-Randomized, Open-Label, Blinded-Endpoint Clinical Trial","MSU-ICH","Inclusion Criteria:\n\n1. History and physical\u002Fneurological examination consistent with acute stroke.\n2. Age ≥18 years;\n3. Time from symptom onset to enrollment \\\u003C3 hours (onset defined as last known normal).\n4. Systolic blood pressure ≥150 mmHg and ≤220 mmHg;\n5. Pre-stroke modified Rankin Scale (mRS) score ≤2;\n6. Informed consent obtained from the subject or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GCS) score ≤5.\n2. Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease.\n3. Malignant disease or other serious primary illness with a life expectancy of \\\u003C3 months.\n4. Current participation in another interventional randomized clinical trial.",{"count":156,"type":22},706,[25],"MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.",[160,161,162,163,164,165,166,167,137,168],"Nervous System Diseases","Cerebrovascular Disorders","Cardiovascular Diseases","Vascular Diseases","Hemorrhage","Intracranial Hemorrhages","Cerebral Hemorrhage","Cerebral Hemorrhage, Hypertensive","Hemorrhagic Stroke, Intracerebral",[170,171,172],"intracerebral hemorrhage","mobile stroke units","Intensive blood pressure lowering","2026-06-18",{"date":94,"type":39},{"date":176,"type":22},"2026-06",{"date":178,"type":22},"2028-07",{"name":45,"class":46},{"id":181,"slug":4,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":191,"conditions":192,"keywords":196,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":203,"leadSponsor":205,"locationsCount":47},"100641226","NCT07658807","Evaluating Bu Yang Huanwu Decoction For Early Diabetic Vascular Disease","Evidence-Based Evaluation and New Drug Translation Research of Early Intervention With the Classic Traditional Chinese Medicine Formula Bu Yang Huanwu Decoction for Preventing and Treating Diabetic Lower Extremity Vascular Disease","Inclusion Criteria:\n\n1. Aged 18 to 70 years (inclusive), male or female.\n2. Diagnosed with diabetes mellitus according to the Chinese Diabetes Society (2024) Guidelines.\n3. Glycated hemoglobin (HbA1c) \\\u003C 12%, with recent fasting blood glucose \\\u003C 7.0 mmol\u002FL OR postprandial blood glucose \\\u003C 10.0 mmol\u002FL, and triglycerides \\\u003C 1.7 mmol\u002FL.\n4. Diagnosed with LEAD, meeting the following criteria:\n\n   Rutherford Classification 2, 3, or 4.\n\n   Resting ABI ≤ 0.90, OR for patients with exertional symptoms and resting ABI \\> 0.90, a post-exercise treadmill test showing an ABI decrease of ≥15%.\n\n   Evidence of lower limb arterial stenosis or occlusion confirmed by duplex ultrasound, CTA, MRA, or DSA.\n5. TCM Pattern Diagnosis: Must conform to the TCM syndrome of Qi Deficiency and Blood Stasis, as defined by the study's TCM diagnostic criteria (referencing \"Practical Diagnostic Criteria for Blood Stasis Syndrome\" and \"Integrated Chinese and Western Medicine Peripheral Vascular Disease\"):\n\n   Main Symptom: Lower limb weakness, or feeling of heaviness\u002Fdiscomfort after prolonged walking.\n\n   Secondary Symptoms: Shortness of breath\u002Flassitude in speaking; dry mouth with desire to drink; scaly skin.\n\n   Tongue \\& Pulse: Tongue with teeth marks, pale-purple with petechiae\u002Fecchymosis; thin and choppy pulse.\n\n   (Diagnosis confirmed by meeting 1 main symptom OR 2 secondary symptoms, assessed by a qualified TCM practitioner.)\n6. Voluntarily signs the Informed Consent Form (ICF) and is willing and able to comply with all study procedures and visits.\n\nExclusion Criteria:\n\n1. Known bleeding disorders or history of intracranial hemorrhage.\n2. Current use of anticoagulants (e.g., warfarin, dabigatran, factor Xa inhibitors).\n3. Presence of active infection.\n4. Severe cardiac abnormalities on resting ECG (e.g., heart failure, ventricular tachycardia, ventricular fibrillation, multifocal ventricular contractions, prolonged corrected QT interval).\n5. History of acute coronary syndrome ≤ 12 months requiring dual antiplatelet therapy.\n6. Chronic liver disease (Child-Turcote-Pugh score ≥5) or chronic kidney disease stages 4-5 (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²).\n7. History of malignancy (except cured basal cell carcinoma).\n8. Moderate to severe anemia, polycythemia vera, or any hyperviscosity syndrome.\n9. Planned lower limb revascularization or amputation.\n10. Concurrent or planned use of medicinal products containing Veratrum species.\n11. Pregnant or lactating women, or women of childbearing potential not using highly effective contraception.\n12. Known allergy or hypersensitivity to any component of the study medication (Qilong Capsules, aspirin).\n13. Patients with psychiatric disorders or judged to be uncooperative.\n14. Currently participating in another drug clinical trial or using therapies with similar purported effects.\n15. Any other condition deemed by the investigator to make the participant unsuitable for the trial.","70 Years",{"count":188,"type":22},300,[190],"PHASE3","The goal of this clinical trial is to learn if adding a Traditional Chinese Medicine formula, Bu Yang Huanwu Decoction (specifically the capsule form called Hua Yu Wan Capsule), to standard treatment can help prevent leg pain at rest or foot ulcers in people with diabetic lower extremity vascular disease. The main questions it aims to answer are:\n\nDoes adding Hua Yu Wan Capsule to standard treatment lower the chance of developing leg pain at rest or foot ulcers after one year, compared to standard treatment alone?\n\nIs the treatment combination safe for participants?\n\nResearchers will compare two groups:\n\nGroup 1 (Experimental): Standard treatment (including aspirin, and medicines for blood sugar and cholesterol control) plus Hua Yu Wan Capsule.\n\nGroup 2 (Control): Standard treatment alone.\n\nParticipants in this study will:\n\nBe adults aged 18 to 70 years with diabetes and early to moderate lower extremity vascular disease (confirmed by tests like the Ankle-Brachial Index or ABI).\n\nBe randomly assigned to one of the two treatment groups.\n\nTake their assigned treatment for 6 months.\n\nAttend clinic visits at 1, 3 and 6 months during treatment, and again at 6 and 12 months after treatment ends for check-ups and tests.",[193,194,195],"Peripheral Arterial Disease","Diabetic Angiopathies","Arterial Occlusive Diseases",[193,197,198,199],"Ischemia","Medicine, Chinese Traditional","Randomized Controlled Trial","2026-06-15",{"date":92,"type":39},{"date":176,"type":22},{"date":204,"type":22},"2029-01",{"name":45,"class":46},{"id":207,"slug":4,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":213,"targetDuration":215,"studyType":82,"phases":4,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":236,"locationsCount":47},"100642500","NCT07620626","Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment","A Real-World Study of Intrasaccular Flow Disruption Devices for the Treatment of Intracranial Aneurysms","WEB-RWS","Inclusion Criteria:\n\nRetrospective Cohort:\n\n* Participants of any age and sex.\n* Patients treated for an intracranial aneurysm using a commercially available MicroVention Woven EndoBridge device.\n* Patients who completed at least one postoperative imaging follow-up.\n\nProspective Cohort:\n\n* Participants of any age and sex.\n* Patients treated for an intracranial aneurysm using a commercially available MicroVention Woven EndoBridge device.\n* The participant, or legally authorized representative if applicable, understands the study requirements and procedures and provides written informed consent before any study-specific data collection.\n\nExclusion Criteria:\n\nRetrospective Cohort:\n\n* Patients treated with a Woven EndoBridge device for whom intraoperative or postoperative follow-up imaging data are not available.\n* Patients considered by the investigator to be unsuitable for participation in this study.\n\nProspective Cohort:\n\n* Participants who are currently participating in, or plan to participate during the follow-up period, another clinical study that may affect the results of this study.\n* Patients who are currently unable or expected to be unable to complete follow-up.\n* Patients with a life expectancy of less than 1 year due to other diseases or conditions.\n* Patients considered by the investigator to be unsuitable for participation in this study.",{"count":214,"type":22},1000,"12 Months","We designed the Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment (WEB-RWS), an ambidirectional, multicenter, post-market real-world study with a prospective active surveillance component. The study will include patients with IAs treated with commercially available WEB devices under the direction of treating physicians in routine clinical practice. Clinical, procedural, imaging, and safety data will be collected using a standardized electronic data capture system, with safety events adjudicated by an independent clinical events committee and imaging outcomes assessed by an independent core laboratory. The primary objective is to evaluate 12-month adequate aneurysm occlusion and major adverse events after WEB treatment. The study is expected to provide comprehensive post-market evidence on the real-world performance of the WEB device in China, including its safety, effectiveness, clinical appropriateness, and health economic value in routine neurointerventional practice.",[218],"Intracranial Aneurysm",[220,221,222,223,218,224,225,226,227,228,229],"Woven EndoBridge","WEB Device","Intrasaccular Flow Disruption","Endovascular Treatment","Aneurysm Embolization","Real-World Study","Post-Market Study","Raymond-Roy Occlusion Classification","WEB Occlusion Scale","Active surveillance","2026-06-09",{"date":232,"type":39},"2026-06-11",{"date":234,"type":22},"2026-06-10",{"date":43,"type":22},{"name":45,"class":46},{"id":238,"slug":4,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":243,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":47},"100515739","NCT05995418","Study on the Health Economic Burden of Alzheimer's Disease in China","The Alzheimer's Disease Burden in China (ABC) Study: a Nationwide Multicentre Cross-sectional and Prospective Cohort Study","Diagnosed according to the National Institute on Aging-Alzheimer's 1.Association (NIA-AA) criteria for aMCI and AD.\n\n2.Clinical Dementia Rating (CDR) score greater than or equal to 0.5 3.Have good visual, auditory, and language functions, or can complete neuropsychological assessments after correction.\n\n4.Participants or their legal representatives sign informed consent. Exclusion criteria\n\n1. History of stroke with neurological focal signs and imaging findings consistent with cerebral small vessel disease (Modified Fazekas score ≥2).\n2. Presence of mental or neurological developmental delay.\n3. Presence of other known conditions that may cause cognitive impairment.\n4. Diagnosis of a disease that prevents completion of cognitive assessments.\n5. Refusal to sign informed consent at baseline.","40 Years","100 Years",{"count":246,"type":22},9510,"Alzheimer's disease (AD) presents a significant socio-economic challenge globally, with China experiencing a notable rise in its prevalence. This study addresses critical gaps in understanding AD's economic burden and quality of life (QoL) impacts on patients and caregivers in Mainland China.",[249],"Alzheimer Disease","2026-06-04",{"date":252,"type":39},"2026-06-05",{"date":254,"type":39},"2023-07-01",{"date":256,"type":22},"2027-01-01",{"name":45,"class":46},{"id":259,"slug":4,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":265,"targetDuration":215,"studyType":82,"phases":4,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":47},"100640833","NCT07604688","Multicenter Registry Study of Patients With Intracranial Dural Arteriovenous Fistulas in China","Dural Arteriovenous Fistulas Registry, Evaluation, and Management Study in China (DREAM)","DREAM","Inclusion Criteria:\n\n* Patients diagnosed with intracranial dural arteriovenous fistula (IDAVF) or spinal dural arteriovenous fistula (SDAVF) by cerebral or spinal digital subtraction angiography (DSA)\n* Patients treated or evaluated at participating centers during the study period\n* Availability of complete clinical and imaging records, including baseline information, treatment records, and DSA images\n* For the prospective cohort, written informed consent signed by the patient or legal representative\n\nExclusion Criteria:\n\n* Patients with facial or scalp arteriovenous fistulas\n* Patients with non-dural vascular malformations or non-arteriovenous fistula vascular diseases, including cavernous malformations or venous malformations",{"count":266,"type":22},10050,"This multicenter registry study aims to clarify the incidence trends of intracranial dural arteriovenous fistulas (IDAVF) and spinal dural arteriovenous fistulas (SDAVF) in China, evaluate current treatment patterns, and establish a nationwide multicenter retrospective and prospective database. The study is designed as a multicenter retrospective and prospective observational study involving more than 60 core hospitals across seven major geographic regions of China. The retrospective phase will include patients diagnosed between February 28, 2015 and February 28, 2025, while the prospective phase will enroll patients from March 1, 2025 to March 1, 2030. Eligible participants are patients diagnosed with IDAVF or SDAVF by digital subtraction angiography (DSA). The study will analyze disease incidence and temporal trends, collect baseline demographic and clinical characteristics, and evaluate treatment outcomes including obliteration rate, recurrence rate, and clinical prognosis. The crude incidence rate per 100,000 person-years during the study period will also be calculated based on Chinese census population data. The primary endpoint is the improvement rate in modified Rankin Scale (mRS) score at 6 months after treatment. Secondary endpoints include obliteration and recurrence rates on imaging follow-up at 6 months and improvement in mRS score at 12 months after treatment. Statistical analyses will be performed using SAS 9.4 software, including descriptive analyses as well as univariate and multivariate regression analyses to identify factors associated with clinical outcomes and prognosis.",[269],"Intracranial Dural Arteriovenous Fistula",[271,272,273,274],"intracranial dural arteriovenous fistula","fistula","malforamtion","outcome",{"date":250,"type":39},{"date":277,"type":22},"2026-05-18",{"date":279,"type":22},"2030-02-28",{"name":45,"class":46},{"id":282,"slug":4,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":287,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":47},"100629805","NCT07479446","Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery","Comparative Study of Oliceridine Versus Sufentanil for Patient-Controlled Intravenous Analgesia in Improving Postoperative Nausea in Patients Undergoing Cerebellopontine Angle Region Surgery.","Inclusion Criteria:\n\n* Scheduled for elective CPA region surgery with planned PCIA.\n* Age 18-65 years.\n* ASA physical status I-III.\n* Provides written informed consent.\n\nExclusion Criteria:\n\n* Opioid tolerance (taking opioids ≥1 week, equivalent to oral morphine ≥50 mg\u002Fday or oxycodone ≥30 mg\u002Fday).\n* Severe cardiopulmonary, hepatic, renal, vascular, neurological, hematological, gastrointestinal, or endocrine diseases.\n* Postoperative ICU admission with tracheal intubation.\n* BMI ≤18.5 or ≥30 kg\u002Fm².\n* Participation in another clinical trial within 3 months prior to screening.",{"count":288,"type":22},174,[25],"This single-center, double-blind, randomized controlled trial aims to determine whether oliceridine for patient-controlled intravenous analgesia (PCIA) can significantly reduce the incidence of postoperative nausea, an opioid-related adverse reaction, compared to sufentanil PCIA in patients undergoing cerebellopontine angle (CPA) region surgery. A secondary objective is to compare the postoperative analgesic effects between the two drugs. The study plans to enroll 174 patients (with a calculated sample size of 164 plus 5% for attrition). The primary outcome is the incidence of nausea within 6-48 hours postoperatively. Secondary outcomes include pain scores at rest and during movement within 48 hours, and other exploratory outcomes such as vomiting incidence, time to first flatus\u002Fdefecation, and gastrointestinal function scores.",[292,293,294,295],"PONV","Cerebellopontine Angle Tumor","Microvascular Decompression Surgery","Postoperative Analgesia","2026-05-20",{"date":298,"type":39},"2026-05-22",{"date":300,"type":39},"2026-03-25",{"date":302,"type":22},"2027-09-30",{"name":45,"class":46},{"id":305,"slug":4,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":17,"minAge":311,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":23,"phases":314,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":47},"100628091","NCT07457125","The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease","The Safety and Preliminary Efficacy of Exosomes Derived From Umbilical Cord Mesenchymal Stem Cell (CB-Exo-A600) in Mild to Moderate Alzheimer's Disease","CB-EXOAD","Inclusion Criteria:\n\n* Age ≥ 50 years, male or female.\n* Clinical diagnosis of AD (mild to moderate stage, corresponding to clinical stage 4-5 at screening according to the 2024 National Institute on Aging\u002FAlzheimer's Association \\[NIA\u002FAA\\] criteria).\n* Patients with cerebrospinal fluid biomarker data supporting an AD diagnosis within the past 3 years, or a positive amyloid Positron Emission Tomography (PET) scan result within the past 3 years, or a plasma p-tau217 test result indicating brain amyloid positivity.\n* Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) scan performed within 6 months prior to screening shows findings consistent with the clinical diagnosis of mild to moderate AD and no other clinically significant comorbid pathologies, particularly cerebrovascular disease. If an MRI or CT scan is not available within the 6 months prior to screening, an MRI must be completed and results confirmed before the subject initiates treatment.\n* Modified Hachinski Ischemic Score (mHIS) ≤ 4.\n* Mini-Mental Status Examination (MMSE) score between 10 and 24 (inclusive).\n* The subject has a clearly identified and reliable caregiver who meets the following criteria: able to independently read and understand relevant study documents at the study site and communicate necessary information with the investigator; willing to comply with clinical study procedures and ensure the provision of accurate information regarding the subject's status throughout the study; resides with the subject or provides care for the subject for no less than 2 hours per day on at least 3 days per week.\n* Female subjects of childbearing potential (including women of reproductive age and those less than 1 year postmenopausal) must use effective contraceptive methods throughout the study.\n* Patients have been on stable doses of cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine, huperzine A), excitatory amino acid receptor antagonists (e.g., memantine), or other cognitive-enhancing medications (e.g., sodium oligomannate) for at least 60 days prior to enrollment and must continue on the same doses throughout the study period.\n* The subject or their legal guardian voluntarily signs a written informed consent form and is able to comply with the study requirements for dosing and follow-up.\n\nExclusion Criteria:\n\n* Patients with a known allergic reaction to the investigational drug or similar drugs.\n* Patients with a known allergic constitution.\n* Previous receipt of umbilical cord mesenchymal stem cell therapy.\n* Laboratory findings (any of the following): absolute neutrophil count \\\u003C 1.0 × 10⁹\u002FL, platelet count \\\u003C 100 × 10⁹\u002FL, serum creatinine \\> upper limit of normal range, serum total bilirubin, alanine aminotransferase, or aspartate aminotransferase \\> 2 × upper limit of normal range.\n* Contraindications for MRI, including but not limited to: presence of cardiac pacemaker, defibrillator, cardiac stent, artificial heart valve, post-aneurysm surgery metal clips, implanted drug infusion device, any implanted electronic device (nerve stimulator, bone growth stimulator), intravascular embolization coils, filters, ECG monitor, metal sutures, shrapnel or buckshot, fracture fixation hardware, cochlear implant, middle ear implant, intraocular metallic foreign body, etc.\n* Subject has Parkinson's disease, multiple cerebral infarction, vascular dementia, Huntington's disease, hydrocephalus, progressive supranuclear palsy, multiple sclerosis, epilepsy, intellectual disability, or a history of significant traumatic brain injury (with or without persistent neurological deficits) or known structural brain abnormalities.\n* Serious systemic infection within 3 months prior to the screening period.\n* Positive for Hepatitis B surface antigen, e antigen, or e antibody, or positive for Hepatitis B core antibody with detectable Hepatitis B virus DNA; positive for Hepatitis C virus antibody; positive for syphilis serology; or positive for Human Immunodeficiency Virus antibody.\n* History of alcohol abuse, drug abuse, or psychiatric illness within 10 years prior to screening.\n* History of malignant tumors.\n* Uncontrolled or poorly controlled cardiovascular, cerebrovascular, hepatic, renal, pulmonary, endocrine or other systemic diseases.\n* Presence of severe aphasia, auditory\u002Fvisual impairment, unstable cardiac arrhythmia, or other severe conditions that would preclude completion of cognitive assessments or receipt of treatment.\n* Any other severe, advanced, or end-stage disease with a life expectancy of less than 12 months.\n* Known pregnancy or breastfeeding, or positive pregnancy test prior to randomization.\n* Current participation in another interventional clinical study that may interfere with outcome assessments.\n* Any other condition deemed by the investigator to make the subject unsuitable for participation or that may pose a significant risk to the patient.","50 Years",{"count":313,"type":22},33,[59,315],"PHASE2","This study is divided into two phases: a dose-escalation phase and an expansion cohort phase. The dose-escalation phase is a single-center study, while the expansion cohort phase is a multicenter, prospective, randomized, double-blind, placebo-controlled study.",[318],"Mild to Moderate Alzheimer's Disease",[320],"Exosomes","2026-05-19",{"date":298,"type":39},{"date":324,"type":22},"2026-05-30",{"date":326,"type":22},"2028-12-30",{"name":45,"class":46},{"id":329,"slug":4,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":334,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":342,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":4},"100637265","NCT07602205","Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A PROBE Clinical Trial","Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A Prospective, Randomized, Parallel-Controlled, Open-Label, Blinded Endpoint (PROBE) Clinical Trial","Inclusion Criteria:\n\n1. A diagnosis of CDKL5 deficiency disorder, including molecular confirmation of a pathogenic CDKL5 variant and exhibiting epileptic seizures.\n2. Male or female participants aged 6 months to 14 years, inclusive.\n3. Patients presenting with drug-resistant epilepsy that seizures were uncontrolled despite the appropriate trial of at least two antiseizure medications (ASMs).\n4. At least 8 motor seizures during each 4 weeks in the 8-week historical seizure records preceding screening.\n5. Treatment regimens of 0-4 ASMs were required to be stable for at least 4 weeks before screening and throughout the intervention. Ongoing ketogenic diets were allowed if remain unchanged during screening and treatment.\n6. Subjects who have undergone surgical implantation of vagus nerve stimulation (VNS) will be eligible for inclusion in the study, provided they meet all of the following criteria:\n\n   1. The VNS device has been in place for at least one year prior to the screening visit;\n   2. The stimulation parameters remain unchanged throughout the duration of the trial.\n7. Parents or caregivers must be able and willing to maintain an accurate and comprehensive daily electronic seizure diary throughout the duration of the study.\n8. Participants' legal guardians willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients who had any history of previous brain disease (including trauma, encephalitis, etc.) that were likely to precipitate seizures; defined by MRI outcomes.\n2. Participants with skin ulceration or dermatologic conditions that make bathing unsuitable.\n3. Parents or guardians who, based on past experiences, determine that the child has an intolerance to thermal baths.\n4. A history of seizures induced by thermal baths, or an increase in seizure frequency after thermal baths.\n5. Patients who presented any clinical condition that in the opinion of the principal investigator made the patient not suitable to participate in the survey.","6 Months","14 Years",{"count":337,"type":22},34,[25],"The primary objective of this research is to study the efficacy and safety of daily, home-based hyperthermic baths for reducing epileptic seizures in CDKL5 Deficiency Disorder.",[341],"CDKL5 Deficiency Disorder",[341,343,344,345,346],"fever","epilepsy","home-based hyperthermic baths","genotype-phenotype","2026-05-15",{"date":298,"type":39},{"date":350,"type":22},"2026-08-01",{"date":352,"type":22},"2027-12-31",{"name":45,"class":46},{"id":355,"slug":4,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":17,"minAge":335,"maxAge":104,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":363,"briefSummary":364,"conditions":365,"keywords":367,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":380},"100631136","NCT07496749","KD Treatment for Super-refractory Status Epilepticus","Ketogenic Diet Treatment for Super-refractory Status Epilepticus: a Multicenter, Prospective, Randomized, Controlled Trial","KD","Inclusion Criteria:\n\n* Patients diagnosed with super-refractory status epilepticus (SRSE), in whom status epilepticus (SE) persists or recurs after the initial treatment for SE-including intravenous benzodiazepines, an anti-seizure medication (ASM, such as valproate, levetiracetam, or phenobarbital), and an anesthetic (e.g., propofol) administered continuously for 24 hours-fails to terminate the episode, or when SE recurs upon reduction of the anesthetic.\n* Age between 14 and 80 years, regardless of gender.\n* The patient's legal guardian has provided signed informed consent.\n\nExclusion Criteria:\n\n* Patients with lipid metabolism disorders, including defects in fatty acid transport and beta-oxidation, such as carnitine deficiency (primary) and carnitine-related enzyme deficiencies (including carnitine palmitoyltransferase \\[CPT\\] I and II deficiency, carnitine translocase deficiency), fatty acid oxidation disorders (including beta-oxidation defects), short-chain acyl-CoA dehydrogenase deficiency (SCAD), medium-chain acyl-CoA dehydrogenase deficiency (MCAD), long-chain acyl-CoA dehydrogenase deficiency (LCAD), long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, medium-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, pyruvate carboxylase deficiency, and porphyria.\n* Intolerance to enteral feeding (e.g., intestinal obstruction).\n* Receipt of propofol infusion within 24 hours.\n* Hemodynamic instability (systolic blood pressure \\\u003C90 mmHg or diastolic blood pressure \\\u003C60 mmHg, requiring high-dose vasopressors for maintenance).\n* Liver failure (aspartate aminotransferase \\[AST\\], alanine aminotransferase \\[ALT\\], blood ammonia \\>5 times the upper limit of normal; total bilirubin \\>10 mg\u002FdL \\[171 μmol\u002FL\\]).\n* Pancreatitis.\n* Pregnancy.\n* Metabolic instability (blood glucose \\\u003C3.1 mmol\u002FL, arterial blood pH \\\u003C7.2, serum sodium \\\u003C120 or \\>160 mmol\u002FL).\n* Septic shock.\n* Complicated by diabetes insipidus.\n* Status epilepticus caused by hypoxic-ischemic brain injury.",{"count":362,"type":22},84,[25],"The purpose of the study is to investigate to evaluate the efficacy and safety of ketogenic diet (KD) as an adjunctive therapy in patients with Super Refractory Status Epilepticus (SRSE) in the intensive care unit (ICU).",[366],"Super-refractory Status Epilepticus",[368,369,370,371,372],"ketogenic diet","status epilepticus","refractory status epilepticus","encephalitis","intensive care unit","2026-05-12",{"date":347,"type":39},{"date":376,"type":39},"2025-10-20",{"date":378,"type":22},"2027-03-01",{"name":45,"class":46},14,{"id":382,"slug":4,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":19,"enrollmentInfo":387,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":402,"locationsCount":47},"100638635","NCT07577323","Safety and Efficacy Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Modulation in Patients With Mild Essential Hypertension","Safety and Efficacy Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Modulation in Patients With Mild Essential Hypertension: A Prospective, Double-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged between 30 and 65 years old.\n2. Office blood pressure with systolic blood pressure (SBP) 140-159 mmHg and\u002For diastolic blood pressure (DBP) 90-99 mmHg.\n3. No intake of any antihypertensive drugs or have discontinued antihypertensive medication for at least 3 months prior to randomization; no intention to receive any other antihypertensive therapy within the 15-week study period.\n4. Written informed consent has been obtained from the subject or their legally authorized representative after being informed of the potential risks.\n\nExclusion Criteria:\n\n1. Known or suspected secondary hypertension.\n2. Contraindications to TI treatment or sham TI treatment, including intracranial metal implants (e.g., pacemaker, ventriculoperitoneal shunt, vascular clip), craniocerebral surgery within the last 6 months, history of intracranial tumor or hemorrhage; skin damage, infection, eczema or allergy at the stimulation site (frontal\u002Ftemporal region); severe skin diseases (e.g., psoriasis).\n3. Subjects with high risk of cerebrovascular disease indicated by cranial magnetic resonance imaging.\n4. History of myocardial infarction or cerebral infarction.\n5. Atrial fibrillation or other severe arrhythmias, such as severe bradycardia, third-degree atrioventricular block, or ventricular tachycardia.\n6. Severe or unstable medical conditions, including severe hepatic dysfunction (defined as alanine transaminase or aspartate transaminase level more than 2 times the upper limit of normal), severe renal dysfunction (defined as serum creatinine level more than 1.5 times the upper limit of normal), and severe heart failure (New York Heart Association Class III and IV).\n7. Females who are pregnant, breastfeeding, or planning to become pregnant within one year.\n8. Individuals unable to cooperate due to mental illness or other reasons.\n9. Participants enrolled in other clinical trials within 3 months prior to randomization.\n10. Participants deemed ineligible for this trial for other reasons determined by the investigator.",{"count":80,"type":22},[25],"The primary objective of this research is to study the efficacy and safety of temporal interference stimulation for blood pressure modulation in patients with mild essential hypertension.",[391],"Essential Hypertension",[393,394,395],"essential hypertension","temporal interference stimulation","TI","2026-05-04",{"date":398,"type":39},"2026-05-11",{"date":400,"type":22},"2026-05-06",{"date":352,"type":22},{"name":45,"class":46},{"id":404,"slug":4,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":409,"targetDuration":4,"studyType":23,"phases":411,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":47},"100636512","NCT07566650","High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) for Hypertension: A Randomized Controlled Trial","A Randomized Controlled Trial of High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) for the Treatment of Essential Hypertension","Inclusion Criteria:\n\n* Clinical diagnosis of primary hypertension (Grade 1-3) as defined by the Chinese Hypertension Guidelines (Revised Edition 2024).\n* For females of childbearing potential, agreement to use contraception during the study.\n* Willing and able to comply with study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Women who are pregnant, breastfeeding, or planning pregnancy during the study period.\n* Resistant hypertension (blood pressure uncontrolled despite adherence to ≥3 antihypertensive drugs of different classes at optimal doses, including a diuretic ), or known secondary hypertension.\n* History of severe cardiovascular or cerebrovascular disease (e.g., myocardial infarction, stroke, heart failure NYHA Class III-IV) within the past 6 months, or severe hepatic or renal dysfunction (defined as ALT\u002FAST \\>3× upper limit of normal \\[ULN\\], or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n* Uncontrolled sleep apnea syndrome, active infectious diseases, chronic wasting diseases, or significant cognitive impairment.\n* Current major psychiatric disorder as assessed by the Mini-International Neuropsychiatric Interview (M.I.N.I.).\n* Contraindications to tACS or MRI: implanted electronic devices, intracranial metal implants, or known history of seizures.\n* Skin lesions, eczema, or broken skin at the intended electrode placement sites.\n* Participation in another clinical trial involving an investigational product or device within 30 days prior to screening.\n* Any condition that, in the opinion of the investigator, would jeopardize the patient's safety or compliance with the study protocol, or interfere with data interpretation.",{"count":410,"type":22},50,[25],"This study focuses on individuals with primary hypertension, with the main objective of investigating the effectiveness and safety of high-intensity transcranial alternating current stimulation (Hi-tACS) as a non-invasive, non-pharmacological treatment for hypertension",[414],"Primary Hypertension",[416,417,418,419],"transcranial alternating current stimulation","autonomic nervous system","neuromodulation","primary hypertension","2026-04-29",{"date":422,"type":39},"2026-05-05",{"date":424,"type":22},"2026-05-01",{"date":426,"type":22},"2028-05-01",{"name":45,"class":46},{"id":429,"slug":4,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":78,"sex":17,"minAge":18,"maxAge":433,"enrollmentInfo":434,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":47},"100635891","NCT07558577","Research on the Application of Sigma Radiopharmaceutical FBFP in Cerebral Stroke","Inclusion Criteria:\n\n1. Angiography diagnosis shows unilateral anterior circulation head and neck artery stenosis with a diameter reduction of\\>70%, and there is no stenosis in the contralateral anterior circulation or bilateral posterior circulation with a diameter reduction of\\>50%;\n2. Transient ischemic attack or ischemic stroke that must have occurred within the past 12 months in the affected vascular area, with the most recent attack lasting more than 3 weeks;\n3. MRI shows no new intracranial infarction lesions;\n4. No previous infarction lesions in the pontine area;\n5. Either PET\u002FMR blood flow or metabolic imaging shows reduced blood flow and metabolism in the affected hemisphere, with a reduction rate exceeding 10% compared to the contralateral region;\n6. Subjects and informants can complete relevant examinations and follow-up work;\n7. The subject or their authorized representative signs the informed consent form.\n\nExclusion Criteria:\n\n1. Poor image quality due to head movement and other reasons during the scanning process.\n2. There are other neurological disorders that can cause brain dysfunction, such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.\n3. There are other systemic diseases that can cause cognitive impairment, such as liver dysfunction, kidney dysfunction, thyroid dysfunction, severe anemia, folate and vitamin B12 deficiency, special infections (such as syphilis, HIV), alcohol and drug abuse, etc.\n4. Existence of mental and neurological developmental delay.\n5. There are other known diseases that may cause cognitive impairment.\n6. Individuals with severe visual and hearing impairments, claustrophobia, and other conditions who cannot cooperate with MRI examinations.\n7. Suffering from diseases that prevent cooperation in completing cognitive examinations.\n8. Refusal to sign informed consent form during baseline period -","99 Years",{"count":410,"type":22},[25],"This clinical research, aims to investigate the uptake of \\[18F\\]FBFP, a Sigma-1 receptor (Sig 1R) PET imaging agent, in stroke participants, compare differences with healthy controls, and evaluate its diagnostic efficacy, providing objective basis for clinical diagnosis and treatment.\n\nThe study will recruit 30 stroke participants (with specific inclusion criteria for unilateral ICA stenosis cases) and 20 gender- and age-matched healthy controls from January 2025 to December 2026. Exclusion criteria cover various neurological and systemic diseases that may affect results, as well as conditions preventing cooperation with examinations.\n\nNo intervention measures are involved. Follow-ups will be conducted at 6 and 12 months to collect clinical data and observe neurological symptom progression. Key measurements include clinical information (via questionnaires and scales like NIHSS and mRS) and PET\u002FMR imaging data (analyzed using PMOD software to calculate SUVmean and uptake differences with cerebellar cortex as reference).\n\nStatistical analysis will use SPSS 21.0, applying descriptive statistics, t-test, ANOVA, regression models, ROC curves, etc., with P \\\u003C 0.05 as significant. Safety evaluation notes PET\u002FMR radiation dose (3-5mSv) is much lower than the safe threshold.\n\nParticipant protection includes ethical approval, informed consent, voluntary participation, risk disclosure, no fees for related exams, and privacy protection. The research team and institution have sufficient resources and qualifications, with outputs including a clinical research cohort and a high-quality paper.",[438,439],"Cerebral Ischemia","PET \u002F MR","2026-04-26",{"date":442,"type":39},"2026-04-30",{"date":444,"type":22},"2026-06-01",{"date":446,"type":22},"2026-12-31",{"name":45,"class":46},{"id":449,"slug":4,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":453,"targetDuration":4,"studyType":23,"phases":455,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":47},"100635894","NCT07558616","Study on the Clinical Efficacy of Transcranial Strong Alternating Current (Hi-tACS) in Patients With Neuroimmune Diseases With Insomnia","Inclusion Criteria:\n\n1. Patients with idiopathic inflammatory demyelinating disorders (IIDDs) meeting the diagnostic criteria, including neuromyelitis optica spectrum disorders (NMOSD) \\[based on the Chinese Guidelines for Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (2016 Edition)\\] and multiple sclerosis (MS) \\[based on the Chinese Guidelines for Diagnosis and Treatment of Multiple Sclerosis (2023 Edition)\\], and accompanied by insomnia.\n\n   * Aged between 18 and 65 years, regardless of gender.\n   * Experiencing difficulty falling asleep, difficulty maintaining sleep, or early morning awakening on at least 3 nights per week for more than 3 months.\n   * Severe daytime functional impairment (Chinese version of the Pittsburgh Sleep Quality Index, item 7 \\[daytime dysfunction\\] ≥2).\n   * Having not taken hypnotics or insomnia treatment medication for at least 4 months.\n   * Female participants aged 18-50 years who agree to use effective contraception throughout the study period.\n   * Agreeing to refrain from receiving medication or other non-pharmacological treatments during the study period.\n   * Agree to participate and sign the informed consent.\n2. Patients diagnosed with chronic primary insomnia according to 《The Diagnostic and Statistical Manual of Mental Disorders》(Text Revision) (DSM-IV-TR) or 《International Classification of Diseases Tenth Revision》(ICD-10):\n\n   * Aged between 18 and 65 years, regardless of gender.\n   * Experiencing difficulty falling asleep, difficulty maintaining sleep, or early morning awakening on at least 3 nights per week for more than 3 months.\n   * Severe daytime functional impairment (Chinese version of the Pittsburgh Sleep Quality Index, item 7 \\[daytime dysfunction\\] ≥2).\n   * Having not taken hypnotics or insomnia treatment medication for at least 4 months.\n   * Female aged 18\\~50 years agreeing to adopt birth control measures during the study period.\n   * Agreeing to refrain from receiving medication or other non-pharmacological treatments during the study period.\n   * Agree to participate and sign the informed consent.\n\nExclusion Criteria:\n\n* History of relapse within the past 1 month.\n* Drug adjustment within the past 1 month, or receipt of modified electroconvulsive therapy, transcranial magnetic stimulation therapy, or other neuralcontroltechnology therapy.\n* Participation in any other clinical studies within 1 month prior to enrollment or currently.\n* Presence of cochlear implant system, cardiac-pacemaker, or intracerebral implanted stimulators.\n* Impaired skin integrity at the electrode placement site, or allergy to electrode gel or adhesive.\n* History of organic brain diseases such as epilepsy, hydrocephalus, tumor of central nervous system, craniocerebral injury, or intracranial infection.\n* Pregnant or lactating women, or those intending pregnancy soon;\n* A score of ≥3 on the suicide item of the Hamilton Depression Scale, or coexisting severe mental disorders;\n* Presence of severe or unstable organic diseases;\n* Work night shifts;\n* Presence of other sleep disorders;\n* Poor patient compliance preventing cooperation with treatment, follow-up, or clinical, electroencephalographic (EEG), or imaging data collection;\n* Other circumstances deemed by the investigator as inappropriate for study participation.",{"count":454,"type":22},80,[25],"This study aims to comprehensively evaluate the therapeutic effects of high-intensity transcranial alternating current stimulation (hi-tACS) on insomnia symptoms in patients with idiopathic inflammatory demyelinating disorders (IIDDs) by analyzing both the overall disease characteristics of IIDDs and individual patient variability. Additionally, the study will investigate the neuroimmunomodulatory mechanisms of hi-tACS. The findings are expected to provide evidence for the clinical application of hi-tACS in managing insomnia in IIDDs and offer new insights for personalized treatment strategies.",[458],"Neuroimmune Diseases With Insomnia",{"date":442,"type":39},{"date":461,"type":39},"2025-09-01",{"date":463,"type":22},"2027-07-31",{"name":45,"class":46},{"id":466,"slug":4,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":11,"sex":17,"minAge":472,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":23,"phases":475,"briefSummary":476,"conditions":477,"keywords":483,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":494},"100623395","NCT07396077","Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II","Multimodal Physiological Reserve Optimizing Prehabilitation Program (PHYSIO-Prehab) in the Chinese Elderly With Spine Surgery","PRACTICE-2","Inclusion Criteria:\n\n1. Aged ≥75 years at the time of screening\n2. Voluntarily sign the informed consent form\n3. Clinically diagnosed with degenerative lumbar spinal disorders with duration of symptoms \\>6 months\n4. Requiring elective lumbar fusion surgery (single-level or multi-level, open or minimally invasive approach)\n5. No severe cognitive impairment (Mini-Mental State Examination score \\> 9)\n6. Scheduled to undergo surgery within 6-8 weeks after screening (allowing completion of the 6-week prehabilitation program)\n\nExclusion Criteria:\n\n1. Scheduled to undergo other emergency surgery or day surgery\n2. Urgent medical conditions requiring priority management before spinal surgery\n3. With spinal disorders other than degenerative diseases (spinal fracture, tumor, metastasis, infection, ankylosing spondylitis, scoliosis with Cobb angle \\>40°)\n4. With contraindications to prehabilitation exercise (New York Heart Association Class IV heart failure, unstable angina, uncontrolled hypertension \\[systolic BP ≥180 mmHg or diastolic BP ≥110 mmHg despite medication\\])\n5. With severe functional disability for other disorders or long-term bedridden status unable to perform basic physical activities\n6. With allergy or intolerance to nutritional supplements used in the prehabilitation program\n7. Participating in another clinical trial involving prehabilitation, perioperative intervention, or spinal surgery within 3 months before screening","75 Years",{"count":474,"type":22},248,[25],"This multicenter, parallel-group, assessor-blinded randomized controlled trial will enroll 248 adults aged ≥75 years with degenerative lumbar spinal diseases scheduled for elective lumbar fusion surgery, and they will be randomized 1:1 into the intervention and usual care groups. The intervention group will receive a 6-week PHYSIO-Prehab multimodal prehabilitation program, including multicomponent exercise, nutritional intervention, comorbidity optimization, and cognitive prehabilitation with brain protection strategies. The control group will receive standard health education provided via a manual, and both groups will receive consistent perioperative Enhanced Recovery After Surgery care. The primary outcome will be the change in Barthel Index (a tool for assessing independence in activities of daily living) from baseline to 30 days postoperatively; secondary outcomes will include pain scores, disability, patient satisfaction, and the 30-day postoperative Comprehensive Complication Index. The trial will initiate recruitment in April 2026 and conclude in December 2027, aiming to evaluate the feasibility and efficacy of PHYSIO-Prehab and provide high-quality evidence for patient-centered perioperative care pathways in this population.",[478,479,480,481,482],"Spine Degeneration","Lumbar Degenerative Disease","Frail Elderly","Enhanced Recovery After Surgery (ERAS) Protocol","Prehabilitation",[482,484,485,486],"ERAS","lumbar fusion","ADL",{"date":488,"type":39},"2026-04-28",{"date":490,"type":39},"2026-04-15",{"date":492,"type":22},"2027-12-30",{"name":45,"class":46},4,{"id":496,"slug":4,"hasResults":11,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":501,"targetDuration":4,"studyType":23,"phases":503,"briefSummary":504,"conditions":505,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":511,"leadSponsor":513,"locationsCount":4},"100634688","NCT07542938","Medeliver Intracranial Drug Coated Balloon Catheter for Symptomatic Intracranial Atherosclerotic Stenosis","Safety and Efficacy of Medeliver Intracranial Drug Coated Balloon Catheter for Symptomatic Intracranial Atherosclerotic Stenosis(Prospective, Multicenter, Randomized Controlled, Superiority Trial)","Inclusion Criteria:\n\n1. Age 18-80 years;\n2. Symptomatic intracranial arterial stenosis within the past 6 months, with 70%-99% diameter stenosis on angiography (per WASID criteria);\n3. Target lesion located in: intracranial segment of the internal carotid artery (C3 or above), M1\u002FM2 segment of the middle cerebral artery, basilar artery, or intracranial segment of the vertebral artery;\n4. At least one atherosclerotic risk factor (history or current hypertension, diabetes mellitus, hyperlipidemia, hyperhomocysteinemia, smoking, or alcohol consumption);\n5. Reference vessel diameter adjacent to the target lesion ≥ 2 mm；\n6. Baseline mRS score ≤ 2;\n7. Patient or legally authorized representative understands the study purpose, voluntarily agrees to participate, provides written informed consent, and is willing and able to comply with follow-up visits.\n\nExclusion Criteria:\n\n1. Acute ischemic stroke within 2 weeks prior to screening;\n2. Major surgery or acute myocardial infarction within 30 days prior to screening;\n3. Intracranial hemorrhage (parenchymal, subarachnoid, subdural, or extradural) within 3 months prior to screening;\n4. Uncontrolled hypertension despite medical therapy (systolic BP ≥ 180 mmHg or diastolic BP ≥ 110 mmHg);\n5. Coexisting intracranial tumor, intracranial aneurysm requiring treatment, or arteriovenous malformation;\n6. Previous stenting of the target lesion or any intracranial stenting\u002Fendovascular procedure within the past 3 months;\n7. Cardioembolic stroke;\n8. Stroke caused solely by perforator artery occlusion;\n9. Two or more consecutive lesions with ≥ 70% stenosis in the target vessel;\n10. Additional de novo or in-stent restenosis lesions (\\> 70% diameter stenosis);in other intracranial arteries requiring treatment during the same session;\n11. Severe calcification, extreme angulation, severe tortuosity, or other anatomical features in the target vessel that may prevent safe device delivery or retrieval;\n12. Known allergy or contraindication to heparin, sirolimus (rapamycin), iodinated contrast, aspirin, clopidogrel, or local anesthetics;\n13. Gastrointestinal bleeding within 6 months prior to informed consent, rendering antiplatelet therapy unsafe;\n14. Platelet count \\\u003C 90 × 10⁹\u002FL;\n15. INR \\> 1.5;\n16. Pregnant, breastfeeding, or planning pregnancy within 1 year;\n17. Life expectancy \\\u003C 1 year;\n18. Participation in another drug or device clinical trial currently or planned during the study period;\n19. Intracranial stenosis due to non-atherosclerotic etiology (e.g., arterial dissection, moyamoya disease, vasculitis, active arteritis, thrombosis);\n20. Severe or unstable comorbidities (e.g., severe heart failure, respiratory failure, renal failure \\[serum creatinine \\> 3.0 mg\u002FdL or 264 µmol\u002FL\\], severe hepatic impairment \\[ALT\u002FAST \\> 3 × ULN\\], active malignancy);\n21. Flow-limiting dissection or residual stenosis \\> 50% after pre-dilatation;\n22. Any other condition that, in the investigator's judgment, makes the patient unsuitable for enrollment;",{"count":502,"type":22},264,[25],"To evaluate the safety and efficacy of the Medeliver® Intracranial Drug-Coated Balloon Catheter (developed by Beijing Jiu Shi Shen Kang Medical Technology Co., Ltd.) in the endovascular treatment of symptomatic intracranial atherosclerotic stenosis.",[506],"Symptomatic Intracranial Atherosclerotic Stenosis","2026-04-17",{"date":509,"type":39},"2026-04-21",{"date":490,"type":22},{"date":512,"type":22},"2027-11-30",{"name":45,"class":46},{"id":515,"slug":4,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":521,"conditions":522,"keywords":523,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":531,"locationsCount":4},"100634841","NCT07544927","Clinical Validation of an Artificial Intelligence-Based Scoring System for the Modified Rankin Scale (mRS) in Patients With Stroke","Inclusion Criteria:\n\n1. Age ≥ 18 years, male or female.\n2. Clinically diagnosed with stroke, and confirmed by cranial CT\u002FMRI to have stroke.\n3. Clinically stable, with basic communication ability at discharge or outpatient visit. The patient or a fixed family caregiver is able to cooperate with telephone follow-up at 1 week after discharge or outpatient visit.\n4. Signed informed consent by the patient or their legally authorized representative.\n\nExclusion Criteria:\n\n1. Neurological deficits caused by non-stroke etiologies (e.g., brain tumor, traumatic brain injury, encephalitis).\n2. Presence of severe disturbance of consciousness, severe cognitive impairment, psychiatric disorders, or global aphasia at discharge\u002Foutpatient visit, preventing effective communication; neither the patient nor family can cooperate with follow-up or assessment.\n3. Combined with severe multi-organ failure (e.g., cardiac, hepatic, renal, respiratory), with an expected survival of less than 1 month, making completion of the 1-week follow-up impossible.\n4. Long-term bedridden without a fixed caregiver, with no confirmed contact for follow-up, or refusal to participate in telephone follow-up and mRS assessment.\n5. Incomplete clinical data, preventing baseline data collection.",{"count":520,"type":22},490,"This study aims to validate the clinical performance of an artificial intelligence (AI)-based automatic scoring system for the Modified Rankin Scale (mRS). The core comparison is the consistency and accuracy between the AI-generated scores and standardized manual mRS follow-up assessments performed by trained professionals. The goal is to provide a convenient, efficient, and objective tool for stroke prognosis assessment, reduce the subjective variability of manual scoring, and optimize the stroke follow-up workflow.",[137],[137,524,525],"Modified Rankin Scale","Artificial Intelligence",{"date":527,"type":39},"2026-04-22",{"date":529,"type":22},"2026-04-10",{"date":69,"type":22},{"name":45,"class":46},{"id":533,"slug":4,"hasResults":11,"nctId":534,"briefTitle":535,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":539,"conditions":540,"keywords":541,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":546,"leadSponsor":547,"locationsCount":4},"100634346","NCT07538492","Clinical Validation of an Artificial Intelligence-Based G-FAST Score in Patients With Stroke","Inclusion Criteria:\n\n1. Aged ≥ 18 years, of either sex.\n2. Clinically diagnosed with stroke, and confirmed by cranial CT\u002FMRI to have ischemic or hemorrhagic stroke.\n3. Onset within 7 days.\n4. Alert and oriented, able to cooperate with standardized video and audio data collection.\n5. The patient or their legally authorized representative understands the study and voluntarily provides written informed consent (including consent for audio-visual data collection).\n\nExclusion Criteria:\n\n1. Neurological deficits caused by non-stroke etiologies (e.g., brain tumor, traumatic brain injury, encephalitis).\n2. Patients with impaired consciousness, severe cognitive dysfunction, or psychiatric disorders that prevent cooperation with video collection and scale assessment.\n3. Patients with severe visual or hearing impairment, or global aphasia, who are unable to follow instructions.\n4. Critically ill patients requiring immediate cardiopulmonary resuscitation or endotracheal intubation, making video and audio data collection impossible.\n5. Patients with severe facial or limb deformities, or large-area dressings that severely interfere with camera data collection.\n6. Patients with unilateral or bilateral upper limb amputation, severe deformity, unhealed fracture, joint fixation, or severe contracture.",{"count":538,"type":22},297,"This study aims to validate the clinical performance of an artificial intelligence (AI)-based automatic assessment system for the G-FAST score. The core comparison is the consistency and accuracy between AI-generated G-FAST results and standardized manual G-FAST assessments performed by trained professionals. The goal is to provide a convenient, efficient, and objective tool for acute stroke screening and early identification, reduce the subjective variability of manual scoring, and optimize the pre-hospital and in-hospital stroke assessment workflow.",[137],[525,542],"G-FAST",{"date":544,"type":39},"2026-04-20",{"date":529,"type":22},{"date":69,"type":22},{"name":45,"class":46},{"id":549,"slug":4,"hasResults":11,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":557,"briefSummary":558,"conditions":559,"keywords":564,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":47},"100566670","NCT06658197","Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke","Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusive Stroke(TNK-LVO) :a Phase 3, Multicentre, Open-label, Randomised Controlled Trial","TNK-LVO","Inclusion Criteria:\n\n1. Age is ≥18 years.\n2. AIS symptom onset ≤4.5 hours, onset time refers to the time the patient was last known to be well. (Recommendation time from thrombolysis to puncture within 60 minutes).\n3. Arterial occlusion of the internal carotid artery (ICA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery on computed tomography angiography (CTA) or magnetic resonance angiography (MRA).\n4. Prestroke mRS score ≤2.\n5. Informed consent from the patient or legally authorised representative.\n\nExclusion Criteria:\n\n1. Patients diagnosed with hemorrhagic stroke (including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural\u002Fextradural hematoma, etc.) or other related conditions identified by CT.\n2. Contraindication to imaging examinations involving contrast agent injection.\n3. Patients presenting with clinical symptoms of coma (NIHSS Score Item 1a = 3).\n4. History of intracranial hemorrhage.\n5. History of severe head trauma or stroke within the past 3 months.\n6. Intracranial or intraspinal surgery within the past 3 months.\n7. Major surgery within the past 2 weeks.\n8. Gastrointestinal or urinary tract bleeding within the past 3 weeks.\n9. Intracranial tumor, arteriovenous malformation, or giant intracranial aneurysm.\n10. Active visceral bleeding.\n11. Aortic arch dissection.\n12. Arterial puncture at a non-compressible site within the past week.\n13. Uncontrolled hypertension despite active antihypertensive treatment: Systolic Blood Pressure \\> 180 mmHg or Diastolic Blood Pressure \\> 100 mmHg.\n14. Acute hemorrhagic tendency, including platelet count \\\u003C 100 × 10⁹\u002FL or other conditions.\n15. Heparin treatment received within the past 24 hours.\n16. For patients on oral anticoagulants: INR \\> 1.7 or PT \\> 15 seconds.\n17. Use of direct thrombin inhibitors or direct Factor Xa inhibitors within the past 48 hours.\n18. Blood glucose \\\u003C 2.8 mmol\u002FL or \\> 22.2 mmol\u002FL.\n19. Hypodensity affecting \\> 1\u002F3 of the middle cerebral artery territory or an equivalent proportion of the basilar artery territory on non-contrast CT.\n20. Rapidly improving symptoms as determined by the investigator.\n21. Participation as a subject in another research study within the past 30 days.\n22. Any terminal illness where life expectancy is considered not to exceed 1 year.\n23. Any condition where, in the judgment of the investigator, the study treatment might pose a risk to the patient or affect the patient's participation in the study.\n24. Pregnant women.\n25. Known allergy to the active ingredients (Alteplase, Tenecteplase) or any excipients.",{"count":556,"type":22},850,[190],"A phase III, multicentre, prospective, randomised, open-label, blinded-endpoint clinical trial will evaluate two thrombolytic agents for the treatment of acute large vessel occlusion stroke within 4.5 hours from symptoms onset: intravenous tenecteplase bridging mechanical thrombectomy vs. intravenous alteplase bridging mechanical thrombectomy.",[560,561,562,563],"Stroke, Ischemic","Stroke, Acute","Thrombosis, Brain","Drug Effect",[565,566],"Ischemic stroke","Tenecteplase","2026-04-08",{"date":569,"type":39},"2026-04-09",{"date":571,"type":39},"2025-12-25",{"date":573,"type":22},"2027-06-01",{"name":45,"class":46},{"id":576,"slug":4,"hasResults":11,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":581,"enrollmentInfo":582,"targetDuration":4,"studyType":23,"phases":584,"briefSummary":586,"conditions":587,"keywords":590,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":599,"leadSponsor":600,"locationsCount":47},"100600318","NCT07095933","The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy","The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy: A Pilot Study","Inclusion Criteria:\n\n* Age between 18 and 60 years (inclusive), regardless of sex.\n* Diagnosis of epilepsy, meeting the criteria for focal seizures or focal to bilateral tonic-clonic seizures as defined by the 2017 International League Against Epilepsy (ILAE) classification.\n* History of epileptic seizures lasting ≥30 seconds, accompanied by impaired awareness.\n* At least 16 focal seizures during the 8-week baseline period prior to enrollment, with no seizure-free interval of 21 consecutive days.\n* Findings on electroencephalography (EEG) or neuroimaging (MRI or CT) performed within 2 years prior to screening consistent with a diagnosis of focal epilepsy, and exclusion of progressive structural central nervous system lesions or progressive encephalopathy.\n* Diagnosis of drug-resistant epilepsy, defined as failure to achieve sustained seizure freedom despite adequate trials of at least two appropriately chosen and tolerated antiseizure medications (ASMs) over a period of 2 years. - Existing ASMs must have no known drug-drug interactions with everolimus and must have been administered at a stable dose for at least 12 weeks prior to enrollment.\n* Use of vagus nerve stimulation (VNS) or deep brain stimulation (DBS) is permitted, provided the device was implanted at least 5 months prior to screening, with stimulation parameters stable for at least 12 weeks before enrollment and maintained unchanged throughout the study.\n* Written informed consent to participate in the study, provided voluntarily by the subject.\n* In the investigator's judgment, the subject is able to comply with the requirements of the study protocol, including understanding and completing seizure diaries, adhering to the visit schedule, and taking study medications as directed.\n\nExclusion Criteria:\n\n* Diagnosis of primary generalized epilepsy.\n* History of non-epileptic events (e.g., psychogenic non-epileptic seizures).\n* Patients with only non-motor focal seizures according to the 2017 ILAE classification.\n* Epilepsy with identifiable and treatable causes (e.g., metabolic disorders, intoxication, infection, space-occupying lesions, or confirmed genetic abnormalities).\n* Inability to accurately count seizures due to excessively frequent episodes within the 12 months prior to study drug administration.\n* History of epileptic seizure clusters within the 12 months prior to study drug administration.\n* History of status epilepticus within the 12 months prior to study drug administration.\n* Use of mTOR pathway inhibitors within the 12 months prior to study drug administration.\n* History of cerebrovascular events (e.g., cerebral infarction, cerebral hemorrhage, or transient ischemic attack) or progressive intracranial lesions within the 6 months prior to study drug administration.\n* Presence of severe uncontrolled diseases, including immunodeficiency disorders, hepatic or renal disease, acute infection, significant pulmonary dysfunction, or advanced malignancy.\n* Severe cardiovascular or peripheral vascular disease, such as New York - Heart Association (NYHA) class III-IV heart failure, malignant arrhythmias (e.g., long QT syndrome, Brugada syndrome, conduction block), any other clinically significant ECG abnormalities, or myocardial infarction within 3 months prior to screening.\n* History of any condition or surgery that, in the investigator's opinion, could affect absorption, distribution, or metabolism of the study drug (e.g., active gastric ulcer, ulcerative colitis, Crohn's disease, intestinal obstruction), or presence of dysphagia.\n* Any medical condition, psychiatric disorder, cognitive impairment, or intellectual disability that, in the investigator's judgment, may increase the risk to the subject or interfere with study participation.\n* Laboratory abnormalities meeting any of the following criteria: alanine aminotransferase (ALT) \\>2× upper limit of normal (ULN), aspartate aminotransferase (AST) \\>2× ULN, alkaline phosphatase (ALP) \\>2× ULN, platelet count \\\u003C80×10⁹\u002FL, neutrophil count \\\u003C1.8×10⁹\u002FL, or creatinine clearance (CLcr) \\\u003C30 mL\u002Fmin (calculated by the Cockcroft-Gault formula).\n* Female subjects who test positive for pregnancy during screening or who are breastfeeding.\n* History of alcohol or substance abuse within 2 years prior to study drug administration.\n* Participation in any other clinical trial within 3 months prior to study drug administration, except for non-interventional clinical trials.\n* Known hypersensitivity or allergy to any component of everolimus tablets.\n* Current use of medications that may affect the central nervous system or the metabolism of everolimus.","60 Years",{"count":583,"type":22},5,[585],"EARLY_PHASE1","The aim of this study is to evaluate the clinical efficacy of everolimus as an adjunctive therapy for refractory epilepsy. The significance lies in addressing whether the mTOR inhibitor sirolimus has antiepileptic adjunctive effects for a broader range of patients with refractory epilepsy, with the hope of providing a new mTOR-targeted antiepileptic adjunctive medication regimen that is administered only during epileptic events and can be widely used for various types of refractory epilepsy.",[588,589],"Epilepsy","Drug Resistant",[591,592,593,594],"Everolimus","Focal Refractory Epilepsy","Epilepsy memory","mTOR pathway","2026-04-05",{"date":597,"type":39},"2026-04-07",{"date":38,"type":22},{"date":446,"type":22},{"name":45,"class":46},{"id":602,"slug":4,"hasResults":11,"nctId":603,"briefTitle":604,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":78,"sex":17,"minAge":18,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":609,"conditions":610,"keywords":612,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":124},"100631285","NCT07498686","Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease","Inclusion Criteria:\n\n\\- Grouping criteria for PD patients: All PD patients who join the group need to meet the following conditions at the same time: The diagnosis of primary PD patients is based on the 2015 International Association for Movement Disorders (MDS) Parkinson's disease diagnosis standard, and all patients need to meet the clinical diagnosis or likely Parkinson's disease diagnosis criteria. Quasi; All patients come from the outpatient clinic of Xuanwu Hospital Affiliated to Capital Medical University, and the clinical evaluation and disease diagnosis are completed by a movement disorder specialist. This project is approved by the Ethics Committee of Xuanwu Hospital Affiliated to Capital Medical University. The subjects who participated in the study signed the informed consent form. Fully improve the information of PD patients and form an NSFC 2024 clinical information database. Establish an evaluation scale based on various indicators such as basic demographic data, general disease status and past history and exercise symptom evaluation, including Hoehn \\& Yahr staging, unified Parkinson's disease assessment scale (MDS- UPDRS), concise mental state examination (MMSE) examination, Monte Lear scale (MOCA), rapid eye movement sleep behavior disorder Hong Kong questionnaire (RBDQ-HK), Hamilton depression scale (HAMD) and anxiety scale (HAMA), integrating a number of sports and non-sports indicators, comprehensively considering and evaluating the patient's condition, for the follow-up relevant Sexual analysis provides accurate and complete clinical information.MSA patients need to meet the MSA clinical diagnosis criteria updated in 2008 by the Europe Multiple System Atrophy Study Group (EMSA-SG). For DLB patients, use the 2017 standard for diagnosis and grouping.\n\nExclusion Criteria:\n\n* Patients with Parkinson's syndrome but not primary PD, patients with brain surgery\u002Fdeep brain electrode stimulation, or patients diagnosed with dementia according to the Diagnostic and Statistical Manual of Mental Illness formulated by the American Association of Mental Illness. PD patients with mild cognitive dysfunction are not excluded.","95 Years",{"count":608,"type":22},458,"Synuclein disease, also known as Synucleinopathies, is a general term for a class of degenerative diseases. It mainly includes Parkinson's disease (PD), Dementia with lewy bodies (DLB), Multiple system atrophy (MSA) and so on. The disease is characterized by the abnormal folding of alpha-synuclein (α-syn) in the peripheral and central nervous system, resulting in the production of lewy bodies, lewy neurites, neurons, and glial cytoplasmic inclusion bodies in neurons or glial cells. The intracellular location and accumulation pattern of α-syn vary in different synuclein diseases. There are overlapping conditions between synuclein diseases, which also makes the accuracy of clinical diagnosis of synuclein diseases very low. A definitive diagnosis can be made only after the patient has died and brain samples are evaluated using immunohistochemical staining. Therefore, in order to intervene and save synuclein disease in advance, it is necessary to develop more accurate and less invasive diagnostic methods.\n\nReal-Time Quaking Induced Conversion (RT-QuIC) is a method for in vitro amplification of pathogenic protein seeds, which can enable seed proteins with in vitro amplification ability to transform substrates into misfolded seeds under specific conditions. RT-QuIC was originally used in the diagnosis of patients with prion protein. The technique can identify the prion protein in the misfolded form in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease with a specificity of 100% and a sensitivity of 95-98%, so it has been incorporated into the clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Studies have shown that pathogenic seeds extracted from patients' cerebrospinal fluid or other biological fluids or tissues are incubated with recombinant protein substrates, and the use of intermittent shaking to promote the interaction between the seed and substrate can force the substrate to transform into pathogenic protein seeds. The RT-QuIC reaction process is monitored in real time by a detector inside the machine for thioflavin, a fluorescent dye that fluoresces when bound to the beta lamellar layer, which is also typical of amyloid fibrils. Studies have shown that testing patients' cerebrospinal fluid with RT-QuIC can accurately distinguish lewy body dementia from non-Parkinson's dementia In this study, RT-QuIC technique was used to amplify the misfolded α-syn in clinical samples to explore the differences in protein characteristics among synuclein diseases, and to try to diagnose synuclein diseases by this method. Firstly, clinical cases of synucleoprotein disease were enrolled, and plasma of 100 control subjects, 221 cases of PD patients and 127 cases MSA patients, 10 cases of PSP patients, were established. Using RT-QuIC technology, we used aSyn (successfully prepared in our laboratory) to amplify the plasma of normal subjects and Synucleinopathies patients. It was found that the maximum fluorescence intensity (extreme value), peak time, K\u002F2 (slope at extreme value\u002F2) and Tmax\u002F2 (time of reaching extreme value\u002F2) can be used as diagnostic and differential diagnostic indicators for Synucleinopathies.",[611],"RT-QuIC",[613],"PD, MSA, PSP, Neurodegeneration disease, alpha-synuclein","2026-03-23",{"date":616,"type":39},"2026-03-27",{"date":618,"type":39},"2023-05-01",{"date":620,"type":22},"2026-12-23",{"name":45,"class":46},""]